This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, Y. Articles by Mallet, W. Search for Related Content PubMed Articles by Chen, Y. Articles by Mallet, W.

Armed Antibodies Targeting the Mucin Repeats of the Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor Models

Departments of ¹ Cancer Pathways and Targets, ² Translational Oncology, ³ Antibody Engineering, ⁴ Protein Chemistry, ⁵ Pathology, and ⁶ Biomedical Imaging, Genentech, Inc., South San Francisco, California

Requests for reprints: William Mallet, Department of Cancer Pathways and Targets, Genentech, Inc., 1 DNA Way MS40, South San Francisco, CA 94080. Phone: 650-225-5717; Fax: 650-225-6443; E-mail: wmallet{at}gene.com.

MUC16 is a well-validated cell surface marker for serous adenocarcinomas of the ovary and other gynecologic malignancies that is distinguished by highly repetitive sequences ("mucin repeats") in the extracellular domain (ECD). We produced and compared two monoclonal antibodies: one (11D10) recognizing a unique, nonrepeating epitope in the ECD and another (3A5) that recognizes the repeats and binds multiple sites on each MUC16 protein. 3A5 conjugated to cytotoxic drugs exhibited superior toxicity against tumor cells in vitro and in tumor xenograft models compared with antibody-drug conjugates of 11D10. Importantly, drug conjugates of 3A5 were well tolerated in primates at levels in excess of therapeutic doses. Additionally, the presence of circulating CA125 in a rat model did not exacerbate the toxicity of 3A5 drug conjugates. We conclude that targeting the repeat MUC16 domains, thereby increasing cell-associated levels of drug-conjugated antibody, provides superior efficacy in vitro and in vivo without compromising safety. [Cancer Res 2007;67(10):4924–32]

This article has been cited by other articles:

				Correction: Armed Anti-MUC16 Antibodies Are Efficacious Cancer Res., June 15, 2007; 67(12): 5998 - 5998. [Full Text] [PDF]